Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients
ESC 2017 - BarcelonaAug. 27, 2017
ESC 2017 Paul Ridker shares what the results of the CANTOS trial mean to him as a clinician. Lowering inflammation by inhibiting IL-1β with canakinumab reduced CV events in aggressively treated CV patients.
This 3-minute education provides a summary of just presented scientific data, recorded during the ESC 2017 congress. The objective is to provide a brief commentary and potential implications of these findings.
Paul M Ridker, MD - Brigham and Women's Hospital, Boston, MA, USA
The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this 3-minute education.